Fund+ Leads EUR38 Million Series B Financing in Indigo Diabetes NV

  • Fund+ strengthens portfolio with medical device company developing a novel ‘invisible’ sensor for diabetes
  • Jan Van den Bossche Partner at Fund+ will join the Board

Belgium, 27 July 2020: Fund+, an investment firm focused on innovative European Life Sciences companies, today announces that it has led the €38 million Series B financing in new portfolio company, Indigo Diabetes (Indigo). Indigo is developing a novel ‘invisible’ continuous glucose monitoring device for diabetics. Jan Van den Bossche, Partner at Fund+, will join the Board.

Read more

By Optimum

For more information about Optimum Strategic Communications, please get in touch

We'd love to hear from you...

GET IN TOUCH